The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton discussed a recent analysis of the ...
The professor of medicine at McMaster University discussed the significance of asundexian’s approval, how a stroke-specific dose-finding approach shaped its development, and what OCEANIC-STROKE showed ...
The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ...
A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated ...
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
The executive vice president of public policy and advocacy at the Muscular Dystrophy Association discusses how NMAC will ...
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential ...
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global ...
Assessing Long-Term Disease Control With Nipocalimab in Pediatric Generalized Myasthenia Gravis: Jonathan Strober, MD In a ...
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, ...
Amanda L. Piquet, MD, reviews 1-year KYSA-8 findings, highlighting sustained clinical improvements and safety outcomes with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results